3665-80-3

Basic information

• Product Name: N-ETHYL-4-NITROANILINE
• Synonyms: Ethyl-(4-nitro-phenyl)-amine;Ethyl-4-nitro-phenyl-amine;n-ethyl-4-nitro-benzenamin;N-Ethyl-4-nitrobenzenamine;N-Ethyl-p-nitroaniline;N-Ethyl-N-(4-nitrophenyl)amine;N-ETHYL-4-NITROANILINE
• CAS NO: 3665-80-3
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.18
• EINECS: 222-927-1
• Product Categories: Amines;C8;Nitrogen Compounds
• Mol File: 3665-80-3.mol
• Article Data: 27

Chemical Properties

• Melting Point: 96-98 °C(lit.)
• Boiling Point: 302.3°Cat760mmHg
• Flash Point: 136.6°C
• Appearance: purple-black crystals, or yellow crystals with a blue-violet lustre
• Density: 1.21g/cm³
• PKA: 0.98±0.32(Predicted)
• Stability: Stable, but may be air sensitive. Incompatible with strong oxidizing agents, strong bases.
• CAS DataBase Reference: N-ETHYL-4-NITROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ETHYL-4-NITROANILINE(3665-80-3)
• EPA Substance Registry System: N-ETHYL-4-NITROANILINE(3665-80-3)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 3665-80-3(Hazardous Substances Data)

Usage

Description

N-Ethyl-4-Nitroaniline is a chemical compound that exists in the form of yellow crystals with a blue-violet luster when obtained from ethanol, or as purple-black crystalline solids. It is known for its chemical properties and is utilized in various applications across different industries.

Uses

1. Propellant Industry:
N-Ethyl-4-Nitroaniline is used as a propellant stabilizer for enhancing the performance and safety of propellants in the propellant industry. Its stabilizing properties help to prevent the decomposition of propellants under various conditions, ensuring a controlled and efficient release of energy.
2. Chemical Synthesis:
N-Ethyl-4-Nitroaniline serves as a building block in the synthesis of various chemical compounds. Its unique structure allows it to be a valuable component in the creation of new molecules with specific properties and applications in different fields, such as pharmaceuticals, dyes, and materials science.

Air & Water Reactions

N-ETHYL-4-NITROANILINE is sensitive to prolonged exposure to air.

Reactivity Profile

N-ETHYL-4-NITROANILINE is basic. Reacts exothermically with acids to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Reaction with strong reducing agents, such as hydrides may generate flammable gaseous hydrogen.

Fire Hazard

Flash point data for N-ETHYL-4-NITROANILINE are not available. N-ETHYL-4-NITROANILINE is probably combustible.

InChI:InChI=1/C8H10N2O2/c1-2-9-7-3-5-8(6-4-7)10(11)12/h3-6,9H,2H2,1H3

Upstream product

• 21614-54-0 4-(ethylamino)-1,2,4-triazole 
• 98-95-3 nitrobenzene 
• 80039-45-8 N-ethyl-4-nitrotrifluoroacetanilide 
• 96-10-6 diethylaluminium chloride 
• 100-01-6 4-nitro-aniline 
• 7647-01-0 hydrogenchloride 
• 529-65-7 N-ethylacetanilide 
• 636-98-6 p-nitrobenzene iodide 
• 627-45-2 N-formylethylamine 
• 586-78-7 para-nitrophenyl bromide 
• 100-00-5 4-chlorobenzonitrile 
• 350-46-9 4-Fluoronitrobenzene 
• 3846-49-9 1,3-diethyl-1,3-bis(4-nitrophenyl)urea 
• 64-19-7 acetic acid 

Downstream Products

• 108485-08-1 N-ethyl-2-bromo-4-nitro-aniline 
• 24827-78-9 1,3-diethyl-1-(4-nitrophenyl)-3-phenylurea 
• 6052-13-7 N-nitro-N-ethyl-2,4,6-trinitroaniline 
• 10220-22-1 1-(4-nitro-phenyl)-pyrrolidine 
• 3846-49-9 1,3-diethyl-1,3-bis(4-nitrophenyl)urea 
• 885057-41-0 tert-butyl (4-aminophenyl)(ethyl)carbamate 

Relevant articles and documents

Direct N-Alkylation/Fluoroalkylation of Amines Using Carboxylic Acids via Transition-Metal-Free Catalysis

A scalable protocol of direct N-mono/di-alkyl/fluoroalkylation of primary/secondary amines has been constructed with various carboxylic acids as coupling agents under the catalysis of a simple air-tolerant inorganic salt, K3PO4. Advantageous features include 100 examples, 10 drugs and drug-like amines, fluorinated complex tertiary amines, gram-scale synthesis and isotope-labelling amine, thus demonstrating the potential applicability in industry of this methodology. The involvement of relatively less reactive silicon-hydride compared with the traditional reactive metal-hydride or boron-hydride species required to reduce the amide intermediates presumably contributes to the remarkable functional group compatibility. (Figure presented.).

Amination of Aromatic Halides and Exploration of the Reactivity Sequence of Aromatic Halides

A base-promoted amination of aromatic halides has been developed using a limited amount of dimethylformamide (DMF) or amine as an amino source. Various aryl halides, including F, Cl, Br, and I, have been successfully aminated in good to excellent yields. Although the amination of aromatic halides with amines or DMF is usually considered as an aromatic nucleophilic substitution (SNAr) process, and the reactivity of an aromatic halide is F > Cl > Br > I, the reactivity of aromatic halides in this system was found to be I > Br a‰ F > Cl. This protocol also showed a good regioselectivity for multihalogenated aromatics. This protocol is valuable for industrial application due to the simplicity of operation, the unrestricted availability of amino sources and aromatic halides, transition metal-free conditions, no requirement for solvent, and scalability.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.